Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
STAR.NS
Strong BuyPremium GrowerStrides Pharma Science Limited · Healthcare · India · $1.2B · Avg Vol: $7M/d
93
StockRankGet insider-trade alerts
Q
69
V
46
M
80
P/E (TTM)
18.0x
ROE
17.9%
D/E
0.6x
Dividend %
0.4%
COMPANY DESCRIPTION
Strides Pharma Science Limited, a pharmaceutical company, engages in the development, manufacturing, and marketing of pharmaceutical products in North America, Australia, Africa, Europe, India, the rest of Asia, and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 36.1B | 37.3B | 43.9B | 46.3B | 8.7% | 50.0B | 55.5B | 65.8B | 19.3% |
| EPS (INR) | -22.49 | -7.76 | 390.55 | 60.34 | -84.5% | 66.49 | 65.29 | 91.60 | 23.2% |
| Shares | 90.3M | 91.9M | 92.2M | 92.2M | +2.1% | 92.2M | — | — | — |
| Debt | 30.3B | 25.2B | 18.8B | 17.6B | -16.6% | 17.6B | — | — | — |
| Equity | 22.1B | 21.3B | 25.5B | 31.1B | 12.0% | — | — | — | — |
| Op CF | 444.1M | 7.0B | 6.8B | 7.0B | 151.0% | 7.0B | — | — | — |
| Inv CF | 3.0B | -1.5B | -896.9M | -1.7B | — | — | — | — | — |
| Fin CF | -2.1B | -6.9B | -6.4B | -4.5B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+12.0%
SMA 50SMA 200
Close
$12.57
RSI (14)
92.4
52W High
$12.88
From 52W High
1.0%
SCORE BREAKDOWN
Quality
69
ROIC
20.3%90.5
ROE
17.9%86.3
GP/Assets
40.6%78.1
Op. Margin
13.7%71.8
FCF/Assets
4.1%65.9
Piotroski
783.9
Int. Cover
5.5x52.7
D/E Ratio
0.56x27.0
Current Ratio
1.25x18.2
Value
46
P/E (TTM)
18.0x65.5
EV/EBITDA
15.3x47.2
P/FCF
38.6x37.6
P/B
3.5x39.7
P/S
2.2x65.9
Div Yield
0.4%12.8
Momentum
80
52W High %
98%98.1
RS 6M
39%88.2
SMA 50/200
1.06x68.8
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+43%50.8
Q Growth
57%76.3
FUNDAMENTALS
Market Cap
$1.2B
P/E (Forward)
12.5x
Gross Margin
56.2%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of STAR.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| STAR.NS | Strides Pharma Science Limited(you) | $1.2B | 93 | Strong Buy |
| AKUMS.NS | Akums Drugs and Pharmaceuticals Limited | $1.2B | 95 | Strong Buy |
| PGHL.NS | Procter & Gamble Health Limited | $981M | 92 | Strong Buy |
| VIYASH.NS | Viyash Scientific Limited | $1.2B | 88 | Strong Buy |
| ALIVUS.NS | Alivus Life Sciences Limited | $1.8B | 91 | Strong Buy |
| BLISSGVS.NS | Bliss GVS Pharma Limited | $810M | 87 | Strong Buy |
| SPARC.NS | Sun Pharma Advanced Research Company Limited | $696M | 89 | Strong Buy |
| IOLCP.NS | IOL Chemicals and Pharmaceuticals Limited | $653M | 89 | Strong Buy |
| APLLTD.NS | Alembic Pharmaceuticals Limited | $1.7B | 84 | Strong Buy |
| MOREPENLAB.NS | Morepen Laboratories Limited | $677M | 85 | Strong Buy |
Peer medians: ROE 11.8% · P/E 42.8x · Gross margin 59.4%